---
title: "Mounjaro (tirzepatide), all indications: Drug interactions questions"
description: "Drug interactions questions on Mounjaro (tirzepatide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does Mounjaro make birth control pills less effective? What drug interactions does Mounjaro have? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/mounjaro/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Mounjaro (tirzepatide), all indications: Drug interactions questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Mounjaro](https://uspl.lilly.com/mounjaro/mounjaro.html#pi)  
Indication pages: [Type 2 diabetes](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes)

## Drug interactions

<a id="mounjaro-birth-control-pills"></a>

### Does Mounjaro make birth control pills less effective?

> “Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Use%20of%20MOUNJARO%20may%20reduce,and%20Clinical%20Pharmacology%20%2812.2%2C%2012.3%29%5D.)

> “Hormonal contraceptives that are not administered orally should not be affected [see Use in Specific Populations (8.3) and Clinical Pharmacology (12.2, 12.3)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Hormonal%20contraceptives%20that%20are%20not,and%20Clinical%20Pharmacology%20%2812.2%2C%2012.3%29%5D.)

> “Following administration of a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) in the presence of a single dose of tirzepatide 5 mg, mean Cmax of ethinyl estradiol, norgestimate, and norelgestromin was reduced by 59%,66%, and 55%, while mean AUC was reduced by 20%, 21%, and 23%, respectively. A delay in tmax of 2.5 to 4.5 hours was observed.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Following%20administration%20of%20a%20combined,to%204.5%20hours%20was%20observed.)

<a id="mounjaro-drug-interactions"></a>

### What drug interactions does Mounjaro have?

> “When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=When%20initiating%20MOUNJARO%2C%20consider%20reducing,%5Bsee%20Warnings%20and%20Precautions%20%285.3%29%5D.)

> “MOUNJARO delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with MOUNJARO.
>
> Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with MOUNJARO.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=MOUNJARO%20delays%20gastric%20emptying%20and%20thereby,when%20concomitantly%20administered%20with%20MOUNJARO.)

> “In vitro studies have shown low potential for tirzepatide to inhibit or induce CYP enzymes, and to inhibit drug transporters.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=In%20vitro%20studies%20have%20shown,and%20to%20inhibit%20drug%20transporters.)

> “Following a first dose of tirzepatide 5 mg, acetaminophen maximum concentration (Cmax) was reduced by 50%, and the median peak plasma concentration (tmax) occurred 1 hour later. After coadministration at week 4, there was no meaningful impact on acetaminophen Cmax and tmax. Overall acetaminophen exposure (AUC0-24hr) was not influenced.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Following%20a%20first%20dose%20of,exposure%20%28AUC0%2D24hr%29%20was%20not%20influenced.)

## Related pages
- [Medical information: Mounjaro (tirzepatide): All indications](https://www.evicenter.com/medical-information/mounjaro)
- [Indication](https://www.evicenter.com/medical-information/mounjaro/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/mounjaro/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/mounjaro/safety)
- [Specific populations](https://www.evicenter.com/medical-information/mounjaro/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/mounjaro/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/mounjaro/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/mounjaro/access-and-coverage)
